- Home
- Industries
Aerospace And Defence
Agriculture
Automotive And Transportation
Banking And Finance
Business
Chemicals And Materials
Consumer And Retail
Electronics And Semiconductors
Food And Beverages
Machinery & Equipments
Manufacturing And Construction
Medical Devices
Others
Pharmaceuticals And Healthcare
Power And Energy
Sports
Technology
- Services
- News Room
- About us
- Contact Us
-
Global Personalized Cancer Vaccine Market Size, Share | CAGR 29.1%
Global Personalized Cancer Vaccine Market Size, Share, Analysis By Technology Platform (mRNA-Based, Cell-Based/Dendritic Cell, Peptide-Based, Viral Vector & DNA Platforms), By Cancer Type (Melanoma, Lung Cancer, Colorectal, Breast, Prostate), By Treatment Approach (Combination Therapy, Monotherapy), By End-User (Hospitals, Specialty Clinics, Academic Research Institutes) Industry Region & Key Players–Segment Overview, Dynamics, Trends & Forecast 2026-2034
Report Overview
| Market Size (2025) | Forecast Value (2034) | CAGR (2026-2034) | Largest Region (2025) |
| USD 685 Million | USD 6.80 Billion | 29.1% | North America, 42.6% |
The Personalized Cancer Vaccine Market was valued at USD 530 Million in 2024 and USD 685 Million in 2025. The market is projected to reach USD 6.80 Billion by 2034, expanding at a CAGR of 29.1% during the forecast period from 2026 to 2034. This represents an absolute dollar opportunity of USD 6.12 Billion over the analysis period.
Personalized Cancer Vaccine Market Global Forecast to 2034 (USD)
CAGR OF
29.1%
Personalized Cancer Vaccine Market
Get more details on this report -
The personalized cancer vaccine market reflects an emerging therapeutic class engineered to target patient-specific tumor neoantigens through mRNA, peptide, DNA, dendritic cell, and viral vector platforms. Clinical momentum accelerated when Moderna and Merck reported on February 9, 2026 sustained 5-year recurrence-free survival benefit for mRNA-4157 (intismeran autogene/V940) plus pembrolizumab in resected high-risk melanoma, with the Phase 3 INTerpath-001 trial of 1,089 patients across 165 sites in 25 countries fully enrolled. The Phase 2b KEYNOTE-942 trial originally demonstrated a 44% reduction in recurrence or death and 65% reduction in distant metastasis risk, which advanced the field from concept to commercial trajectory.
Regulatory anchors are substantial. The FDA granted Breakthrough Therapy Designation to mRNA-4157/V940 in combination with KEYTRUDA for adjuvant high-risk melanoma in 2023, and the European Medicines Agency granted PRIME (Priority Medicines) scheme designation in parallel. The FDA's Center for Biologics Evaluation and Research (CBER) governs personalized cancer vaccine submissions under the BLA pathway, while 21 CFR Part 312 IND requirements apply to investigational protocols. The MHRA, NMPA, and PMDA align with international guidance through the International Council for Harmonisation, supporting global multi-regional Phase 3 designs.
Technology innovation is consolidating around two operational architectures. The first uses mRNA encapsulated in lipid nanoparticles, exemplified by Moderna's mRNA-4157 (encoding up to 34 neoantigens) and BioNTech's autogene cevumeran (encoding up to 20 neoantigens, co-developed with Genentech). The second uses peptide, DNA, dendritic cell, or viral vector formats, exemplified by Evaxion A/S's EVX-01 peptide platform, Nykode Therapeutics' Vaccibody DNA technology, Transgene's myvac MVA viral vector, and Geneos Therapeutics' GT-EPICT plasmid platform. AI-driven neoantigen prediction is now central to all leading platforms.
Regionally, North America held 42.6% revenue share in the personalized cancer vaccine market in 2025, anchored by FDA leadership, NIH and National Cancer Institute funding, and concentrated venture activity in Boston, Cambridge, and Plymouth Meeting. Europe captured 28.4% share with Germany (BioNTech SE), the United Kingdom (BioNTech-UK Government partnership), and France (Transgene SA) as anchor countries. Outlook through 2034 hinges on Phase 3 readouts of mRNA-4157 in melanoma and NSCLC, BioNTech's autogene cevumeran in pancreatic ductal adenocarcinoma and urothelial carcinoma, and the timing of first BLA filings expected from 2027 onward.
Market Definition and Scope
The personalized cancer vaccine market is defined as the segment of immuno-oncology in which therapeutic vaccines are custom-designed for individual patients based on the unique somatic mutations and neoantigens identified through whole-exome sequencing and RNA sequencing of the patient's own tumor. The market encompasses mRNA-based, peptide-based, DNA-based, dendritic cell, and viral vector platforms intended to elicit tumor-specific T cell responses for adjuvant, neoadjuvant, or metastatic-setting treatment.
This analysis covers clinical trial revenue, platform licensing payments, milestone-based collaboration economics, and projected commercial sales attributable to personalized vaccine assets. It includes Moderna's INTerpath program, BioNTech's iNeST portfolio, Transgene's myvac platform, Nykode Therapeutics' Vaccibody system, Evaxion's AI-Immunology platform, and Geneos Therapeutics' GT-EPICT system. Excluded from this scope are off-the-shelf cancer vaccines (Provenge for prostate cancer, BCG for bladder cancer, HPV preventive vaccines), shared neoantigen vaccines without patient-level customization, and broad cancer immunotherapy categories such as checkpoint inhibitors and CAR-T cell therapies. The parent therapeutic cancer vaccine market reached approximately USD 6.8 Billion in 2025; personalized vaccines represented approximately 10.1% of that parent.
Key Takeaways
- Market Growth: The personalized cancer vaccine market expanded from USD 685 Million in 2025 toward a projected USD 6.80 Billion by 2034, registering a CAGR of 29.1% during the forecast period.
- Segment Dominance by Technology: mRNA-based platforms captured approximately 38.0% share in 2025, anchored by Moderna's mRNA-4157 and BioNTech's autogene cevumeran encoding up to 34 and 20 neoantigens respectively.
- Segment Dominance by Cancer Type: Melanoma indications represented 26.0% of platform value in 2025 driven by KEYNOTE-942 and INTerpath-001 momentum, while non-small cell lung cancer (NSCLC) represented 22.0% as INTerpath-002 and INTerpath-009 expanded.
- Driver: Sustained 5-year recurrence-free survival benefit for mRNA-4157 plus pembrolizumab reported February 9, 2026 in the KEYNOTE-942 follow-up reduced clinical-risk discounts and re-rated the entire personalized vaccine asset class.
- Restraint: Manufacturing turnaround time per patient remains 6 to 12 weeks from biopsy to first dose, with cost per personalized vaccine course estimated at USD 100,000 to USD 250,000, constraining adjuvant population eligibility and complicating reimbursement models.
- Opportunity: The pancreatic ductal adenocarcinoma indication, with a 5-year overall survival rate of 8 to 10% and recurrence rates near 80% post-resection, represents an addressable opportunity exceeding USD 2 Billion if BioNTech's autogene cevumeran Phase 2 IMCODE-003 trial in 260 patients confirms Phase 1 signals of 50% durable T cell response.
- Trend: AI-driven neoantigen prediction is now standard, with Evaxion A/S's AI-Immunology platform reporting 86% vaccine target precision at AACR 2026 in San Diego on April 22, 2026.
- Regional: North America held the largest regional share at 42.6%, equating to approximately USD 292 Million in 2025, with the United States accounting for the bulk via concentrated NCI Cancer Center trial activity and FDA Breakthrough Therapy Designations.
Key Insights Summary
- Moderna and Merck reported sustained 5-year recurrence-free survival benefit for mRNA-4157 (intismeran autogene/V940) plus pembrolizumab versus pembrolizumab alone in resected high-risk melanoma on February 9, 2026, building on the 44% reduction in recurrence or death observed in the Phase 2b KEYNOTE-942 trial of 157 patients.
- The pivotal Phase 3 INTerpath-001 trial of mRNA-4157 in resected high-risk Stage IIB-IV melanoma is fully enrolled at 1,089 patients across 165 sites in over 25 countries, evaluating recurrence-free survival as the primary endpoint per Merck and Moderna disclosures.
- BioNTech's autogene cevumeran (BNT122/RO7198457) demonstrated polyspecific T cell responses persisting up to 4 years in 8 of 16 patients with resected pancreatic ductal adenocarcinoma in a Phase 1 trial published in Nature in 2023, with hazard ratio of 0.08 favoring vaccine responders.
- Evaxion A/S presented data at AACR 2026 on April 22, 2026 in San Diego demonstrating that 86% of vaccine targets in EVX-01 elicited tumor-specific immune responses, a target-precision rate higher than reported for competing AI methods.
- BioNTech committed up to GBP 1 Billion (approximately USD 1.33 Billion) over 10 years to UK research and development on May 20, 2025, supported by up to GBP 129 Million in UK government grants, with R&D centers planned in Cambridge and London targeting personalized cancer immunotherapies for up to 10,000 NHS patients by 2030.
- The personalized vaccine production cycle requires biopsy, whole-exome sequencing, RNA sequencing, neoantigen prediction, mRNA or peptide synthesis, lipid nanoparticle formulation, and quality release, totaling 6 to 12 weeks from tissue receipt to first patient dose.
Competitive Landscape Overview
The personalized cancer vaccine market is moderately consolidated at the late clinical stage and fragmented earlier in the pipeline. The combined share of the top four players, Moderna Inc., BioNTech SE, Merck & Co. Inc., and F. Hoffmann-La Roche AG, reached approximately 71% of platform-attributable value in 2025. Competition is technology-led and partnership-led rather than price-led, with mRNA dominating late-stage development and peptide, DNA, viral vector, and dendritic cell platforms competing in earlier indications. The competitive frontier is shifting from monotherapy efficacy to combination architecture: virtually all leading programs are studied in combination with anti-PD-1 (pembrolizumab, nivolumab) or anti-PD-L1 (atezolizumab) checkpoint inhibitors. New entrants include Evaxion A/S, myNEO Therapeutics, Geneos Therapeutics, and NeoCura, each backed by AI-driven neoantigen prediction platforms. Notable exits include Gritstone bio, which filed Chapter 11 in October 2024 and sold its main asset package to Seattle Project Corp. for USD 21.25 Million, with bankruptcy plan effectiveness on April 4, 2025.
Competitive Landscape Matrix
| Company Name | Headquarters | Market Position | Key Product / Solution | Geographic Strength | Recent Strategic Move |
| Moderna, Inc. | Cambridge, USA | Leader | mRNA-4157 (intismeran autogene/V940) | North America, Global | 5-year RFS data in melanoma reported February 9, 2026 |
| BioNTech SE | Mainz, Germany | Leader | Autogene cevumeran (BNT122) iNeST platform | Europe, North America | GBP 1 Billion UK investment announced May 20, 2025 |
| Merck & Co., Inc. | Rahway, USA | Leader | KEYTRUDA combination partner; INTerpath sponsor | North America, Global | INTerpath-009 NSCLC Phase 3 dosing began December 2025 |
| F. Hoffmann-La Roche AG | Basel, Switzerland | Leader | Genentech-sponsored autogene cevumeran in PDAC, urothelial | Europe, North America | Phase 2 IMCODE004 urothelial cancer enrollment resumed 2025 |
| Transgene SA | Illkirch-Graffenstaden, France | Challenger | myvac (TG4050) MVA viral vector platform | Europe, Asia | Phase 2 head and neck cancer trial readouts ongoing |
| Nykode Therapeutics ASA | Oslo, Norway | Challenger | Vaccibody plasmid DNA platform | Europe | Genentech termination effective January 6, 2025 |
| Evaxion A/S | Copenhagen, Denmark | Niche Player | EVX-01 peptide vaccine; AI-Immunology platform | Europe | AACR data showing 86% target precision, April 17, 2026 |
| Geneos Therapeutics | Plymouth Meeting, USA | Niche Player | GT-EPICT platform; GNOS-PV02 hepatocellular | United States | Phase 2 hepatocellular carcinoma trial enrollment |
| NEC Corporation | Tokyo, Japan | Niche Player | AI neoantigen prediction (with Transgene) | Asia, Europe | Expanded Transgene collaboration October 2024 |
| myNEO Therapeutics | Ghent, Belgium | Niche Player | ImmunoEngine AI platform | Europe | Strategic partnerships expanded 2025 |
By Technology Platform
The personalized cancer vaccine market by technology platform is led by mRNA-based vaccines, which captured approximately 38.0% share in 2025. Moderna's mRNA-4157 and BioNTech's autogene cevumeran anchor this segment, leveraging lipid nanoparticle delivery validated through SARS-CoV-2 vaccine programs to encode patient-specific neoantigens. mRNA platforms compress production timelines, with manufacturing achievable within 6 to 8 weeks of biopsy. Recent advances in AI-guided neoantigen selection by Moderna's mRNA Design Studio and BioNTech's iNeST architecture support continued segment leadership through 2034.
Peptide-based vaccines represented approximately 22.0% of segment value in 2025, anchored by Evaxion A/S's EVX-01, Geneos Therapeutics' personalized neoantigen peptide approach, and academic programs such as Memorial Sloan Kettering Cancer Center's PGV001 (presented at the Icahn School of Medicine in March 2025). Peptide vaccines offer manufacturing simplicity and well-characterized adjuvants such as Poly-ICLC. DNA-based vaccines captured 14.0% share, led by Nykode Therapeutics' Vaccibody plasmid platform encoding up to 20 neoantigens with antigen-presenting cell targeting units.
Dendritic cell vaccines accounted for 16.0% share in 2025, anchored by autologous DC platforms across academic centers and specialty biotech. Viral vector platforms captured 10.0% share, led by Transgene's myvac (TG4050) using modified vaccinia virus Ankara, partnered with NEC Corporation since 2024 for AI neoantigen prediction. Comparison: mRNA platforms hold a 1.7x value advantage over peptide platforms because lipid nanoparticle delivery enables both Class I and Class II antigen presentation in vivo, whereas peptide vaccines require carefully optimized adjuvants to achieve comparable T cell priming.
By Cancer Type
The personalized cancer vaccine market by cancer type is led by melanoma at 26.0% share in 2025, encompassing resected high-risk Stage IIB-IV melanoma in adjuvant and neoadjuvant settings. The KEYNOTE-942 trial showing 44% reduction in recurrence or death and the fully-enrolled Phase 3 INTerpath-001 trial define the lead indication. NSCLC captured 22.0% share, supported by INTerpath-002 (NCT06077760) and INTerpath-009 (NCT06623422) targeting 680 patients with resected Stage II-IIIB NSCLC who did not achieve pathological complete response after neoadjuvant pembrolizumab plus chemotherapy. Pancreatic ductal adenocarcinoma represented 12.0% share, with autogene cevumeran's IMCODE-003 Phase 2 enrolling 260 patients, expected to read out in mid-2027.
Colorectal cancer accounted for 10.0% share, with mixed signals: BioNTech's BNT122-01 trial in adjuvant ctDNA+ Stage II/III CRC crossed the futility boundary at first interim analysis disclosed in early 2026, while Moderna and Merck's INTerpath-007 evaluates V940 in cutaneous squamous cell carcinoma. Bladder/urothelial captured 8.0% share through INTerpath-005 and IMCODE-004 (which resumed enrollment in 2025 after a brief safety pause). Glioblastoma held 7.0% share led by CureVac's CVGBM, which induced de novo T cell responses in 77% of trial patients. Breast cancer (6.0%), hepatocellular carcinoma (4.0%), and other solid tumors (5.0%) round out the indication mix.
By Treatment Approach
The personalized cancer vaccine market by treatment approach is led by combination therapy, which captured approximately 66.0% share in 2025. Combinations with anti-PD-1 antibodies (pembrolizumab, nivolumab) and anti-PD-L1 antibodies (atezolizumab) reflect immunological synergy: vaccines prime tumor-specific T cells while checkpoint inhibitors prevent T cell exhaustion. Monotherapy use captured 34.0% share, primarily in early-stage clinical investigation and in indications where checkpoint blockade is not standard of care. Triple combinations adding chemotherapy backbones (mFOLFIRINOX in PDAC) are emerging in pancreatic and colorectal trials. For procurement leads at NCI-designated Comprehensive Cancer Centers evaluating personalized vaccine implementation, the combination architecture decision drives reimbursement coding strategy under CMS Part B drug billing pathways.
By End-User
The personalized cancer vaccine market by end-user is led by hospitals, including academic medical centers and NCI-designated Comprehensive Cancer Centers, at 36.0% share in 2025. Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, MD Anderson Cancer Center, and Johns Hopkins Kimmel Cancer Center anchor United States trial activity. Cancer research institutes captured 32.0% share, including the Icahn School of Medicine at Mount Sinai (PGV001 program), the Olayan Center for Cancer Vaccines at MSK, and Genomics England (UK Cancer Vaccine Launch Pad). Specialty oncology clinics held 18.0% share, while in-house biopharma R&D operations captured 14.0%. ROI calculation for personalized cancer vaccine implementation must account for sequencing infrastructure (illumina NovaSeq capacity), bioinformatics workflow, GMP-compliant vaccine manufacturing access (in-house or via Lonza, Catalent, or BioNTech's network), and supply chain coordination spanning 6 to 12 weeks from tissue receipt to first patient dose.
Regional Analysis
The personalized cancer vaccine market by region is led by North America at 42.6% revenue share in 2025, equating to approximately USD 292 Million. The United States dominates with FDA Breakthrough Therapy Designations (mRNA-4157 in 2023), National Cancer Institute funding through the NCI Cancer Centers Program, and concentrated venture funding in Boston, Cambridge, and Plymouth Meeting. Canada hosts INTerpath-009 NSCLC Phase 3 enrollment activity that began in late 2025. Mexico's role remains limited. Recent developments include Moderna and Merck's 5-year RFS data on February 9, 2026 and the initiation of NSCLC Phase 3 dosing in December 2025.
Europe held 28.4% share in 2025, equivalent to USD 195 Million. Germany anchors the region through BioNTech SE's Mainz headquarters and its iNeST platform development. The United Kingdom plays a strategic role through BioNTech's GBP 1 Billion (approximately USD 1.33 Billion) 10-year R&D investment announced May 20, 2025, supported by up to GBP 129 Million in UK government grants. The Cambridge R&D center will focus on genomics, oncology, and structural biology with capacity for more than 90 scientists; the London hub will house an AI center led by InstaDeep. France contributes through Transgene SA (Illkirch-Graffenstaden), Norway through Nykode Therapeutics ASA (Oslo), and Denmark through Evaxion A/S (Copenhagen). The European Medicines Agency granted PRIME designation to mRNA-4157, accelerating European market access.
Asia Pacific captured 19.7% share in 2025, valued at approximately USD 135 Million. Japan contributes through NEC Corporation's expanded October 2024 collaboration with Transgene to develop AI-driven neoantigen prediction engines for personalized vaccines, supported by Japan's Moonshot R&D Program and PMDA regulatory pathways. China leads through NeoCura, BeiGene, and JW Therapeutics, supported by China's Healthy China 2030 strategy and growing NMPA submissions for personalized oncology. South Korea is investing in mRNA manufacturing capabilities, while Australia hosts Phase 1 dosing for multiple international personalized vaccine trials. Asia Pacific is expected to grow at the fastest CAGR through the forecast period.
Latin America held 5.5% share in 2025, approximately USD 38 Million, with Brazil and Mexico as principal demand markets. Anvisa review pathways align with FDA decisions for breakthrough designations, accelerating market access. Local trial infrastructure remains concentrated in Sao Paulo and Mexico City.
The Middle East and Africa contributed 3.8% share, valued at approximately USD 26 Million in 2025. Israel anchors through academic partnerships with Memorial Sloan Kettering and Dana-Farber, while Saudi Arabia's Vision 2030 healthcare investments expanded specialty cancer center infrastructure. The United Arab Emirates' Department of Health Abu Dhabi facilitated cross-border patient access to personalized vaccine trials at Cleveland Clinic Abu Dhabi during 2025.
Country Analysis
United States
The personalized cancer vaccine market in the United States was valued at approximately USD 263 Million in 2025 and is projected to grow at a CAGR of 29.4% during 2025-2034. The FDA's Center for Biologics Evaluation and Research governs personalized vaccine BLA submissions, having granted Breakthrough Therapy Designation to mRNA-4157 in 2023. The National Institutes of Health and NCI fund research through the NCI Cancer Moonshot program, while the Department of Defense produced a portable transdermal vaccine delivery prototype in 2025 for remote and military settings. State-level initiatives include the Texas Cancer Prevention and Research Institute (CPRIT) and the Massachusetts Life Sciences Center, which back Boston-area mRNA innovation.
Germany
Germany's personalized cancer vaccine market reached approximately USD 89 Million in 2025 with a country CAGR of 30.2% during 2025-2034. BioNTech SE anchors domestic activity, having developed the iNeST platform and the autogene cevumeran (BNT122) program in collaboration with Genentech. The Paul-Ehrlich-Institut governs IND-equivalent submissions and aligns with EMA pathways. Germany's Federal Ministry of Education and Research funds mRNA technology infrastructure, while CureVac (Tubingen) advances unmodified mRNA cancer vaccines including CVGBM in glioblastoma. The Helmholtz Munich and DKFZ Heidelberg partnerships expand academic-industry collaboration.
United Kingdom
The United Kingdom's personalized cancer vaccine market reached approximately USD 56 Million in 2025 with a country CAGR of 32.6%, supported by BioNTech's GBP 1 Billion R&D investment announced May 20, 2025. The NHS Cancer Vaccine Launch Pad (CVLP), led by NHS England in partnership with Genomics England, targets enrollment of up to 10,000 patients by 2030. University Hospitals Birmingham NHS Foundation Trust hosts ongoing mRNA cancer vaccine trials in colorectal cancer. The Medicines and Healthcare products Regulatory Agency (MHRA) maintains expedited review pathways for breakthrough oncology assets.
China
China's personalized cancer vaccine market reached approximately USD 57 Million in 2025 with a country CAGR of 33.8% during 2025-2034. The NMPA approved expedited review pathways for mRNA cancer vaccines under its Priority Review program. Chinese biotech firms including NeoCura, BeiGene, and JW Therapeutics operate personalized oncology platforms, while Healthy China 2030 strategy supports public funding for precision oncology. The CSCO (Chinese Society of Clinical Oncology) issues clinical practice guidelines that increasingly reference combination immunotherapy approaches relevant to vaccine pairing strategies.
Personalized Cancer Vaccine Market
Size, by Region, 2025-2034 (USD)
The Market will Grow
At the CAGR of:
29.1%
The Forecast Market
Size for 2034 in USD:
$USD 6.80 B
Get more details on this report -
Key Market Segments
By Technology Platform
- mRNA-Based Cancer Vaccines
- DNA-Based Cancer Vaccines
- Peptide-Based Cancer Vaccines
- Neoantigen-Based Vaccines
- Viral Vector-Based Vaccines
- Others
By Cancer Type
- Melanoma
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Others
By Treatment Approach
- Monotherapy
- Combination Therapy
- Others
By End-User
- Hospitals
- Cancer Treatment Centers
- Academic and Research Institutes
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations (CROs)
- Specialty Oncology Clinics
- Government Research Organizations
- Others
By Regional Coverage
- North America
- Latin America
- East Asia And Pacific
- Sea And South Asia
- Eastern Europe
- Western Europe
- Middle East & Africa
| Report Attribute | Details |
| Market size (2025) | USD 685 M |
| Forecast Revenue (2034) | USD 6.80 B |
| CAGR (2025-2034) | 29.1% |
| Historical data | 2021-2024 |
| Base Year For Estimation | 2025 |
| Forecast Period | 2026-2034 |
| Report coverage | Revenue Forecast, Competitive Landscape, Market Dynamics, Growth Factors, Trends and Recent Developments |
| Segments covered | By Technology Platform, (mRNA-Based Cancer Vaccines, DNA-Based Cancer Vaccines, Peptide-Based Cancer Vaccines, Neoantigen-Based Vaccines, Viral Vector-Based Vaccines, Others), By Cancer Type, (Melanoma, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Others), By Treatment Approach, (Monotherapy, Combination Therapy , Others), By End-User, (Hospitals, Cancer Treatment Centers, Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), Specialty Oncology Clinics, Government Research Organizations, Others) |
| Research Methodology |
|
| Regional scope |
|
| Competitive Landscape | MODERNA, INC., BIONTECH SE, MERCK & CO., INC., F. HOFFMANN-LA ROCHE AG, TRANSGENE SA, NYKODE THERAPEUTICS ASA, EVAXION A/S, GENEOS THERAPEUTICS, INC., NEC CORPORATION, MYNEO THERAPEUTICS, CUREVAC SE, OSE IMMUNOTHERAPEUTICS, NOUSCOM AG, IO BIOTECH, INC., PDS BIOTECHNOLOGY CORP., TUHURA BIOSCIENCES, NEOCURA, IMMUNOMIC THERAPEUTICS, INC., ULTIMOVACS ASA, Others |
| Customization Scope | Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements. |
| Pricing and Purchase Options | Avail customized purchase options to meet your exact research needs. We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF). |
Frequently Asked Questions
How big is the Personalized Cancer Vaccine Market?
The Global Personalized Cancer Vaccine Market was valued at USD 530 Million in 2024 and USD 685 Million in 2025, and is projected to reach USD 6.80 Billion by 2034, growing at a CAGR of 29.1% from 2026 to 2034. Market growth is driven by precision oncology, mRNA vaccines, neoantigen-based immunotherapy, and personalized cancer treatments.
Who are the major players in the Personalized Cancer Vaccine Market?
MODERNA, INC., BIONTECH SE, MERCK & CO., INC., F. HOFFMANN-LA ROCHE AG, TRANSGENE SA, NYKODE THERAPEUTICS ASA, EVAXION A/S, GENEOS THERAPEUTICS, INC., NEC CORPORATION, MYNEO THERAPEUTICS, CUREVAC SE, OSE IMMUNOTHERAPEUTICS, NOUSCOM AG, IO BIOTECH, INC., PDS BIOTECHNOLOGY CORP., TUHURA BIOSCIENCES, NEOCURA, IMMUNOMIC THERAPEUTICS, INC., ULTIMOVACS ASA, Others
Which segments covered the Personalized Cancer Vaccine Market?
By Technology Platform, (mRNA-Based Cancer Vaccines, DNA-Based Cancer Vaccines, Peptide-Based Cancer Vaccines, Neoantigen-Based Vaccines, Viral Vector-Based Vaccines, Others), By Cancer Type, (Melanoma, Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Others), By Treatment Approach, (Monotherapy, Combination Therapy , Others), By End-User, (Hospitals, Cancer Treatment Centers, Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), Specialty Oncology Clinics, Government Research Organizations, Others)
How can this market research report help my business make strategic decisions?
Our market research reports provide actionable intelligence, including verified market size data, CAGR projections, competitive benchmarking, and segment-level opportunity analysis. These insights support strategic planning, investment decisions, product development, and market entry strategies for enterprises and startups alike.
How frequently is the data updated?
We continuously monitor industry developments and update our reports to reflect regulatory changes, technological advancements, and macroeconomic shifts. Updated editions ensure you receive the latest market intelligence.
Select Licence Type
Connect with our sales team
Personalized Cancer Vaccine Market
Published Date : 30 Jun 2026 | Formats :Why IntelEvoResearch
100%
Customer
Satisfaction
24x7+
Availability - we are always
there when you need us
200+
Fortune 50 Companies trust
IntelEvoResearch
80%
of our reports are exclusive
and first in the industry
100%
more data
and analysis
1000+
reports published
till date